139 related articles for article (PubMed ID: 12614625)
1. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
2. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
3. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
4. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Zhang B; Peng ZY
Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
[TBL] [Abstract][Full Text] [Related]
5. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
Byeon IJ; Li J; Ericson K; Selby TL; Tevelev A; Kim HJ; O'Maille P; Tsai MD
Mol Cell; 1998 Feb; 1(3):421-31. PubMed ID: 9660926
[TBL] [Abstract][Full Text] [Related]
7. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.
Mahajan A; Guo Y; Yuan C; Weghorst CM; Tsai MD; Li J
J Mol Biol; 2007 Nov; 373(4):990-1005. PubMed ID: 17881001
[TBL] [Abstract][Full Text] [Related]
8. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.
Boice JA; Fairman R
Protein Sci; 1996 Sep; 5(9):1776-84. PubMed ID: 8880901
[TBL] [Abstract][Full Text] [Related]
11. Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16 INK4A.
Li J; Qin D; Knobloch TJ; Tsai MD; Weghorst CM; Melvin WS; Muscarella P
Biochem Biophys Res Commun; 2003 May; 304(2):241-7. PubMed ID: 12711305
[TBL] [Abstract][Full Text] [Related]
12. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
14. A minimum folding unit in the ankyrin repeat protein p16(INK4).
Zhang B; Peng Zy
J Mol Biol; 2000 Jun; 299(4):1121-32. PubMed ID: 10843863
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of p16INK4A correlates with Cdk4 association.
Gump J; Stokoe D; McCormick F
J Biol Chem; 2003 Feb; 278(9):6619-22. PubMed ID: 12529334
[TBL] [Abstract][Full Text] [Related]
17. Stability and folding of the tumour suppressor protein p16.
Tang KS; Guralnick BJ; Wang WK; Fersht AR; Itzhaki LS
J Mol Biol; 1999 Jan; 285(4):1869-86. PubMed ID: 9917418
[TBL] [Abstract][Full Text] [Related]
18. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
Coleman KG; Wautlet BS; Morrissey D; Mulheron J; Sedman SA; Brinkley P; Price S; Webster KR
J Biol Chem; 1997 Jul; 272(30):18869-74. PubMed ID: 9228064
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism.
Tevelev A; Byeon IJ; Selby T; Ericson K; Kim HJ; Kraynov V; Tsai MD
Biochemistry; 1996 Jul; 35(29):9475-87. PubMed ID: 8755727
[TBL] [Abstract][Full Text] [Related]
20. Protein folding and stability of human CDK inhibitor p19(INK4d).
Zeeb M; Rösner H; Zeslawski W; Canet D; Holak TA; Balbach J
J Mol Biol; 2002 Jan; 315(3):447-57. PubMed ID: 11786024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
